No Acute Changes in LVEF Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses

Bian, Shelly X.; Korah, M.P.; Whitaker, Taylor R.; Ji, Lingyun; Groshen, Susan; Chung, Eugene H.

doi:10.1016/j.clbc.2017.03.011

Cited by 11 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was similar to what other studies concluded. 1,[33][34][35][36] As for the other primary outcome, we also found that there is no statistically significant increase in ischemic heart disease due to RT (P = .619). Other studies have shown that RT causes an increase in the incidence of CVEs when combined with trastuzumab.…”

Section: Discussionmentioning

confidence: 52%

Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab

Bachir

Anouti

Jaoude

et al. 2022

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 52%

Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab

Bachir

Anouti

Jaoude

et al. 2022

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…In particular, a mean dose to the left ventricle of 9 + 4 Gy was significantly correlated with a reduced anterior wall strain (-16.8% at 14 months after RT), an early surrogate marker of myocardial function detectable with doppler echocardiographic imaging. Conversely, in patients with relatively low MHD (< 4 Gy), Bian et al found no association between cardiac dosimetry and left ventricular ejection fraction (LVEF) ( 86 ). Multiple heart dose parameters have been associated with clinically relevant cardiotoxicity in breast cancer ( 87 ).…”

Section: Breast Radiotherapy: Heartmentioning

confidence: 99%

Application of Radiomics for the Prediction of Radiation-Induced Toxicity in the IMRT Era: Current State-of-the-Art

et al. 2020

View full text Add to dashboard Cite

Normal tissue complication probability (NTCP) models that were formulated in the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) are one of the pillars in support of everyday's clinical radiation oncology. Because of steady therapeutic refinements and the availability of cutting-edge technical solutions, the ceiling of organsat-risk-sparing has been reached for photon-based intensity modulated radiotherapy (IMRT). The possibility to capture heterogeneity of patients and tissues in the prediction of toxicity is still an unmet need in modern radiation therapy. Potentially, a major step towards a wider therapeutic index could be obtained from refined assessment of radiation-induced morbidity at an individual level. The rising integration of quantitative imaging and machine learning applications into radiation oncology workflow offers an unprecedented opportunity to further explore the biologic interplay underlying the normal tissue response to radiation. Based on these premises, in this review we focused on the current-state-of-the-art on the use of radiomics for the prediction of toxicity in the field of head and neck, lung, breast and prostate radiotherapy.

show abstract

“…Mean heart dose for right and left-sided treatment was 1.1 and 3.63 Gy, respectively. There was a 3% decrease in LVEF overall with significant correlation with receiving doxorubicin but no correlation to radiation laterality of dose (21). This would suggest that lower doses of radiation do not significantly amplify cardiotoxic effect of chemotherapy.…”

Section: Late Cardiac Toxicitymentioning

confidence: 86%

Late complications of radiation therapy for breast cancer: evolution in techniques and risk over time

Brownlee¹,

Garg²,

Listo³

et al. 2018

Gland Surg.

View full text Add to dashboard Cite

Radiation therapy in combination with surgery, chemotherapy, and endocrine therapy as indicated, has led to excellent local and distant control of early stage breast cancers. With the majority of these patients surviving long term, mitigating the probability and severity of late toxicities is vital. Radiation to the breast, with or without additional fields for nodal coverage, has the potential to negatively impact long term cosmetic outcome of the treated breast as well as cause rare, but severe, complications due to incidental dosage to the heart, lungs and contralateral breast. The long-term clinical side-effects of breast radiation have been studied extensively. This review aims to discuss the risk of developing late complications following breast radiation and how modern techniques can be used to diminish these risks.

show abstract

No Acute Changes in LVEF Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses

Abstract: With cardiac doses < 4 Gy, declines in LVEF were not related to tumor laterality or heart dosimetric parameters. Statistically significant LVEF decreases were mainly attributed to doxorubicin.

Cited by 11 publications

References 17 publications

Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab

Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab

Application of Radiomics for the Prediction of Radiation-Induced Toxicity in the IMRT Era: Current State-of-the-Art

Late complications of radiation therapy for breast cancer: evolution in techniques and risk over time

Contact Info

Product

Resources

About